[go: up one dir, main page]

WO2018190781A1 - Amélioration de systèmes de cartographie électro-anatomique tridimensionnelle traditionnelle sur la base de mesure de potentiel électrique par cartographie de signal de champ magnétique biologique endocardique : cartographie de tissu conducteur cardiaque - Google Patents

Amélioration de systèmes de cartographie électro-anatomique tridimensionnelle traditionnelle sur la base de mesure de potentiel électrique par cartographie de signal de champ magnétique biologique endocardique : cartographie de tissu conducteur cardiaque Download PDF

Info

Publication number
WO2018190781A1
WO2018190781A1 PCT/TR2017/050230 TR2017050230W WO2018190781A1 WO 2018190781 A1 WO2018190781 A1 WO 2018190781A1 TR 2017050230 W TR2017050230 W TR 2017050230W WO 2018190781 A1 WO2018190781 A1 WO 2018190781A1
Authority
WO
WIPO (PCT)
Prior art keywords
signals
signal
magnetic field
mapping
activity
Prior art date
Application number
PCT/TR2017/050230
Other languages
English (en)
Inventor
Sinan Altan KOCAMAN
Original Assignee
Kocaman Sinan Altan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kocaman Sinan Altan filed Critical Kocaman Sinan Altan
Publication of WO2018190781A1 publication Critical patent/WO2018190781A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/25—Bioelectric electrodes therefor
    • A61B5/279—Bioelectric electrodes therefor specially adapted for particular uses
    • A61B5/28—Bioelectric electrodes therefor specially adapted for particular uses for electrocardiography [ECG]
    • A61B5/283—Invasive
    • A61B5/287—Holders for multiple electrodes, e.g. electrode catheters for electrophysiological study [EPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6852—Catheters
    • A61B5/6857—Catheters with a distal pigtail shape
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6867—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive specially adapted to be attached or implanted in a specific body part
    • A61B5/6869—Heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7282—Event detection, e.g. detecting unique waveforms indicative of a medical condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2505/00—Evaluating, monitoring or diagnosing in the context of a particular type of medical care
    • A61B2505/05—Surgical care
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02—Details of sensors specially adapted for in-vivo measurements
    • A61B2562/0223—Magnetic field sensors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A61B5/346—Analysis of electrocardiograms
    • A61B5/349—Detecting specific parameters of the electrocardiograph cycle

Definitions

  • the invention relates to a device for use in diagnosis and treatment of cardiac rhythm disorders. It is aimed to use this device to map the specialized conductive tissue and cardiac muscle tissue by novel 3-dimensional (3D) endocardial biological magnetic field signal mapping with traditional electropotential measurement based 3D electroanatomical mapping system.
  • the cardiac specialized conductive tissue cannot be mapped 3-dimentionally by separating it from the myopotentials on muscle tissue.
  • the 3D mapping of thi s structure wi 11 be abl e to offer new treatment opti ons whi I e maki ng the di agnosti c mappi ng easier to treat the cardiac arrhythmias.
  • rhythm problems originated by heart's specialized conductive tissue and muscle tissue are traditionally treated by the measurement of electrical membrane potentials of myocardium and their temporal-spatial differences which is measured by the electrophysiology catheter, placed inside the heart under X -ray fluoroscopy.
  • the actual 3D electroanatomical mapping methods have been developed, which are provided by a 3D visual platform of electropotential measurements from the inner surface of the heart. Recent developments on these methods are intended to increase the electropotential measuring electrodes (poles) on the mapping catheter. By this approach, mapping will be created in less time and at a higher resolution.
  • 3D map of heart ' s specialized conductive tissue cannot be distinguished from muscle tissue by those methods based on electro- potential measurement.
  • the electropotentials that occur in conductive system and muscle tissue do not have a separable feature, apart from time difference of stimulation. Therefore, the only way to distinguish conductive system from muscle tissue in traditional methods is to place the mapping catheter on conductive tissue and to try finding its confined exact location in which the signal formation is earlier than muscle tissue. But it is not practically possible to find conductive tissue and side branches one by one, and to contact all of them at the same time. Moreover by the approach, the entire conductive system cannot be mapped in 3D. If the device described in this invention, it would be able to distinguish these two tissues from each other by using differences of them, such as frequency band, excitation time, amplitude, activation direction and location information of the biological magnetic field signals originating from conductive system and muscle tissue.
  • Hybrid signal collector catheter Fig. 1
  • tissue contact for Hybrid signal collector catheter Fig. 1 to collect the biological magnetic field signals inside heart is not necessary.
  • the catheter does not touch the area of interest the system with sensors located on 3-axis can localize the biological magnetic field signals (these signals are generated by direct electrical current created by depolarization wave in conductive system) originated from the conductive system perceived at the same time from one or more points, using reverse problem-solving technique.
  • the initiator or driver of many cardiac arrhythmias are originated from the specialized cardiac conductive system.
  • a device that displays the specialized cardiac conductive system separating it from myocardial tissue may help us to develop new treatment approaches, by overcoming limitations of available methods and, it may also offer curative methods in complex arrhythmias, such as atrial fibrillation, which is not understood at the moment precisely and therefore it cannot be cured completely.
  • electrophysiologist evaluates the conductive system, he/she will be able to directly observe the progression of activation wave on conductive system, instead of using indirect measurement and maneuvers. This observation can also be performed when arrhythmia begins, and it can be understood whether source of arrhythmia is within conductive system or myocardial tissue, or it would be able to determine if conductive tissue is a critical part of the arrhythmia.
  • the new device will able to eliminate use of indirect stimulation or measurement methods in most of cases.
  • Non-fluoroscopic 3D electroanatomical mapping methods measure membrane potential differences on myocyte membranes in terms of volts.
  • instant-point mapping of conductive system is performed by contacting with electrophysiology catheters the region where the conductive system is estimated.
  • intended points can be positioned on a platform of 3D electropotential maps.
  • the activation map shows electrical spread at muscle level, not at the level of conductive system. For this reason, the activation pathway of arrhythmia can be seen as a wide myocardial area, not along a line. Therefore, the cardiac electrophysiologist must test these signals with conventional tissue contact and stimulation methods, by approaching to the related target area with mapping catheter.
  • a traditional 3D method if a critical treatment target is identified, ablation of a large area, rather than a point for treatment, is necessary. Therefore, it is possible to damage normal conductive system with these large ablations, and it can also result in unnecessary ablati on or therapy fai I ure caused by not abl e to reach the origi nal source.
  • magnetic sensors are used (CA RTO, E nsite etc.).
  • these sensors are not used to measure biological magnetic field signals; they are used to determine the coordinates of mapping or ablation catheters in the 3D environment.
  • current techniques to measure the biological magnetic signals of heart have been tested with sensors placed outside the body until now. The most important problem of these systems is that they are away from the biological signal source, especially cardiac specialized conductive system.
  • a second major disadvantage is that heart is a moving structure and these sensors are fixed outside the body and do not move with heart. This situation leads to a significant motion artifact and reduction of resolution in the map.
  • Hybrid signal collector catheter that provides high- resolution magnetic field imaging, moves with the heart inside heart chambers and it can be positioned at points ranging from centimeter (cm) to millimeter (mm) in distance to the biological magnetic signal source. This significantly increases resolution of the map of the magnetic field signal.
  • the cardiac arrhythmias may develop in structurally normal-looking hearts or they may develop in sick hearts after remodeling, which occurs in the course of acquired coronary heart disease or valvular heart disease.
  • cardiac arrhythmias ultimately affect heart muscle, main source of them is the specialized conductive system.
  • it is difficult to restrict the signal source to a precise point on conductive system. For this reason, ablation is frequently performed on large myocardial areas involved in arrhythmia.
  • cardiac conductive pathway network map in 3D environment by pulsed biological magnetic field signals in heart (beginning from a point and spreading) and its integration with current 3D electroanatomical mapping, will allow electrophysiologist to apply the treatment on a detailed, actual cardiac anatomy in arrhythmia therapy.
  • mapping catheter can only map inside heart chamber of interest, where catheter is located, because the current electroanatomical mapping requires electrode contact to the tissue.
  • absolute contact of Hybrid catheter for acquisition of magnetic field signals is not required. Therefore, Hybrid catheter can also capture and map the magnetic field activity in adjacent heart chamber without approaching it.
  • complex arrhythmias using multiple accessory pathways, arrhythmia sources are not localized by the conventional 3D method, arrhythmia caused by Purkinje fibers can also be treated without loss of time and need of a complex procedure.
  • the new mapping system will also improve the success rate of treatment in some arrhythmias that cannot be tolerated by the patient, because it will provide a faster 3D map than the conventional method and it will provide a more rapid approach to the source by revealing the source of the problem more accurately and clearly.
  • F ig. 1 Hybrid signal collector catheter specifications (simultaneously senses the electropotential and magnetic field signals)
  • F 1-A Hybrid catheter view from side perspective (in use configuration)
  • F ig. 2 Algorithm for matching with the source of biological magnetic field signals detected at activation time intervals, that are defined by the heart's specific electroanatomic and magnetic signal reference points in the heart prior to mapping
  • F2-A, Surface E C G recordings Lead DI and DII (12 leads are used in the system), P wave (atrial activity on the surface E CG), QRS complex (ventricular activation on the surface E CG), T wave (ventricular repolarization), PRI (PR interval)
  • H RA high right atrium
  • HIS prox-dist. HIS prox-dist.
  • CS coronary sinus signals
  • RVA right ventricular apex signals
  • H H
  • H H
  • H H
  • H activity signals V
  • V ventricular electropotential
  • A atrial electropotential
  • PA PA interval
  • a H AH interval
  • HV HV interval
  • F2-C Algorithm for matching with the source of biological magnetic field signals detected at activation time intervals (AIs) defined by the heart's specific electroanatomic and magnetic signal reference points (R Ps) inside the heart prior to mapping and the forward and backward signal analyses (FSA and BSA) for system signal identification
  • AIs activation time intervals
  • R Ps electroanatomic and magnetic signal reference points
  • FSA and BSA forward and backward signal analyses
  • F ig. 3 Methods for collecting and storing of position/location information of the sensor and biological magnetic field sources in defined time intervals of the heart cycle in mapping
  • Hybrid catheter apparatus with mechanisms for maneuvering at the distal end
  • hybrid catheter body main shaft
  • distal ring of Hybrid catheter end portion that can be maneuvered from the proximal portion of the catheter
  • the hybrid catheter connection point (the port for data transferring of the distal catheter sensors to the system and for signal sending from the system to the transmitter at distal portion of the catheter for coordinate information production)
  • M 1-3 Built-in magnetometer sensors in the hybrid catheter (M1, at the tip/distal of the catheter; M2, in the body of the catheter ring portion and M3, in the shaft of the catheter). These sensors are placed in 3 dimensional environments at perpendicular coordinates to each other on the catheter.
  • H 1-20 E lectrode poles placed in the distal ring of Hybrid catheter for electropotential measurement (each pair of electrodes measures voltage of the contact area between them)
  • R P-2 The first magnetic field signal detected by the system on basal activity in the atrium (it originates from the beginning of SA node activity)
  • R P-3 T he begi nni ng of the P wave on the surface E C G or starti ng poi nt of the A wave on the catheter settled in the H RA inside the heart (it is caused by the depolarization of the atrium muscle).
  • R P-4) Intracardiac HIS activation beginning point (it is marked when the hybrid catheter is located on the HIS bundle).
  • AI 1-12 When the patient is in the sinus rhythm, these time intervals are defined for the system according to the reference points (RP 1-6) before the mapping (at these time intervals, the system identifies all magnetic field signals by the forward and backward signal analyzes and, it matches them with their sources).
  • This interval includes a sampling interval of 20 milliseconds (ms) after the end of T wave indicating the end of the previous beat. It is the defined time interval after the point marked as R P-1 in the system (it provides a sampling time of up to 2% of the cardiac cycle). Since there is no any mappable activation (depolarization) in this interval on heart ' s conductive system, the system determines the baseline signal (BA) activity here. FSA-1 analysis is carried through this time interval. The system uses all signal activity detected here to exclude from the map in the filtering process.
  • AI-2 In this time interval, only sinoatrial node activity (SA) is present.
  • SA sinoatrial node activity
  • the evaluation of this interval is performed by signal scanning in two directions (forward and backward direction).
  • the system also performs a second control scanning.
  • the system performs backward analysis from R P-3 to RP-1 by BSA-1 analysis.
  • the first detected magnetic wave belongs to the atrial conductive system (AC S) and the second detected wave belongs to the SA node activity.
  • AC S atrial conductive system
  • This time interval includes the interval from the RP-3 to the SA activity during backward scan of signals.
  • the system performs BSA -2 within this interval. In this interval prior to RP-3, the SA and the conductive system activities may overlap. For this reason, sequences of these signals are important to assign them to the system.
  • the system by BSA-2 identifies signal of the conductive tissue within 10 ms prior to RP-3 and in the time interval immediately before it also defines the SA activity.
  • This time interval is the scan of 40 ms after RP-3.
  • the system performs FSA-3 at this interval.
  • the atrial muscle tissue (A) and atrial conductive system (AC S) are actived simultaneously.
  • the system basically separates the ACS signals from the atrial muscle tissue signals with frequency difference.
  • AI-5) This time interval includes 20 ms before the AV node activity. This time interval is also analyzed by 2- directional signal analysis. These are FSA-3 and BSA-3. First, in this time interval, forward FSA-3 is performed from RP-3 to RP-4. R P-4 is HIS activation. The first new magnetic field frequency after the AI-4 corresponds to the AV activity. This point (the beginning of the AV node activation) determines the end of the AI-5. In BSA-3 control analysis, during backward signal scan from RP-4 to RP-3 within 100 ms prior to HIS activity, the first different frequency belongs to AV node (the hybrid catheter is located on the HIS). Scanning of the 20 ms prior to the AV node activity sequence will give the time interval of A 1-5.
  • This time interval includes the AV node activity. It covers a time interval of about 75 ms. This interval is also confirmed by a two-directional signal scan. In this interval, FSA-3 and BSA-3 signal analyses are performed. This interval is defined as the time of 75 ms after the end of AI-5 during the FSA-3 scan.
  • first organized frequency group belongs to the AV node.
  • BSA-3 backward control analysis
  • first detected signal originates from the junctional region activity (J R, fast and/or slow AV pathway conduction, and if it exists, isolated junctional activity occurs here).
  • J R junctional region activity
  • J R fast and/or slow AV pathway conduction
  • This time interval is the conductive tissue activity from the RP-4 up to the time of the AV node activity during backward signal scanning. It probably can reflect slow and fast AV pathways and the junctional activity. This time interval is defined by analyzing with FSA-3 and BSA-3.
  • This time interval is evaluated in two-di recti on with signal analysis of FSA-4 and BSA- 4. It includes the time period of 50 ms (5% of the heart cycle) after RP-4 during forward scan (FSA-4) from RP-4 to RP-5. It includes the magnetic field activity up to the Purkinje activity (PJ ) during the FSA-4 analysis. In this interval, the infra-HIS conductive system is activated (the right and left bundle branch and their branches). In addition, the ongoing depolarization of the left atrium muscle can be detected in this interval.
  • the backward scan analysis (BSA-4) is performed from RP-5 to RP-4. The time interval from the end of Purkinje activity until the beginning of HIS activity is analyzed.
  • the infra-HIS conduction system map is created with biological magnetic signals in this time interval.
  • RP-5 is the earliest beginning point of the QRS complex on the patient's 12 lead surface E CG and the earliest V wave on intracardiac recordings.
  • the time interval of 20 ms before RP-5 defines this interval.
  • BSA-5 is performed in this interval and the system primarily defines PJ activity here.
  • This time interval is the scan of 100 ms after RP-5 (10% of the heart cycle).
  • the signal scanning is performed by FSA-5.
  • the PJ activity in the conduction system and the signals of the ventricular muscle depolarization are recorded.
  • only signals in frequency band of conducting system are used in mapping.
  • the device records the instantaneous data, which is measured for every thousandths of cardiac cycle (for example, for every 1 ms in a heart cycle of 1000 ms), into separately defined timeslots throughout heart cycle focusing on activation wave magnetic signal frequency.
  • signals are recorded when hybrid catheter is at a fixed point.
  • the information about instant location of the conduction system depolarization wave signal, whose frequency is defined by the system before mapping, is separately calculated for the 3 magnetosensors in hybrid catheter using the reverse problem solving technique for each timeslot.
  • system creates a new 3D conduction system map when the sensor is located at the same point.
  • the arithmetic mean points of the conduction system pathway coordinates which are determined for every timeslot in each heartbeat are positioned by their time and 3D coordinate information on the conduction system network.
  • the device collects a location information for same timeslot of heart cycle while hybrid catheter is in different positions and compares this information with location data obtained from different sensors.
  • signal location data defined for a specific timeslot in each heart cycle is verified for different sensor locations (F3-B).
  • the device defines the timeslots in thousandths of the cycle along a heart cycle (for example, a timeslot includes 1 ms in a heart cycle of 1000 ms).
  • a timeslot includes 1 ms in a heart cycle of 1000 ms.
  • the collected magnetic signal locations are re-recorded in each heartbeat for a defi ned ti mesl ot ( i nto same ti mesl ot for every heart beat) .
  • system When the sensor is moved to different coordinates inside the heart chamber, system records the arithmetic mean of magnetic field signal location data received over a defined timeslot in each cardiac cycle (for example 140th ms).
  • F3-3 When the sensor is located at a given coordinate, system records the activation wave magnetic field signals with their coordinates for all of the defined timeslot in the heart cycle (such as 10th, 30th, 50th or 140th ms) separately. This location data is calculated for each new heart cycle and stored in a defined timeslot with the arithmetic average.
  • F3-4 The network of conduction system is entirely visualized with signals of biological magnetic fields, calculated by the coordinates of signals originating simultaneously from one or more conduction pathway. At consecutive timeslots of heart cycle, signal locations are combined on a 3D position data plot. In this way, system creates a 3D signal location data plot against timeslots.
  • the heart has a network of electrical conduction system similar to nerve cells.
  • changes on the cellular membrane potential produce pulsed electrical direct currents (DC). These currents then spread to the myocardial cells.
  • E lectrical direct current in these tissues leads to the formation of magnetic fields in conductive tissue cells and muscle cells.
  • the magnetic fields created by cardiac muscle cells and specialized conduction system can be dissociated from each other in several ways. The differences in these two tissues help us to distinguish their signals.
  • the new system has the capability of a hybrid working with state-of-art electroanatomical mapping systems.
  • the device includes a special hybrid catheter that collects the electropotentials and endocardial biological magnetic field signals from the inner surface of heart.
  • connection cables that transmit these signals to the computer system and hybrid surface equipment with magnetic and electropotential sensors, which receives the coordinate information of magnetic sensors on hybrid catheter and transmits it to the mapping system are also required.
  • An analyzer that includes software that operates algorithms for identifying the frequency (wavelength), amplitude, location and phase (stimulation sequence) of magnetic field waves on specialized conductive tissue and muscle tissue and executes methods for separating of these signals from each other and also uses the signal collecting and data storage algorithms to create the 3D map of the conduction system.
  • a computer where the 3D map will be created; a monitor that reflects the generated 3D map; and a hardware required for the system in which all equipment works together are also required in new system.
  • the new 3D mapping system/device that maps endocardial biological magnetic field signals will able to work as a hybrid with current 3D electroanatomical systems.
  • the features of the new mappi ng system are as f ol I ows:
  • Hybrid signal collector catheter A special catheter that simultaneously measures the heart's biological magnetic field signals and electropotential data from the inside of heart and it also sends them to the system along with location information of the sensor.
  • Signal acquisition and analysis of signal sources, and introduction to mapping system Software that calculates time intervals defined in heart cycle according to certain electroanatomic and biological magnetic field signal references and it analyzes the sources of the signals at these intervals, it also processes and classifies the signals along this way.
  • Signal analysis Software that processes and classifies (separation of the signals) the endocardial biological magnetic field signals collected from specialized conductive tissue and muscle tissue, using their time, frequency and amplitude values
  • Data storage The software that stores the collected biological magnetic field signals to defined timeslots in heart cycle and to defined location in 3D model, and performs the comparison of data collected with different methods for the same time and location.
  • the device that has the capability of a hybrid working with state-of-art electroanatomical mapping systems includes a special hybrid catheter that simultaneously collects electropotentials and endocardial biological magnetic field signals from inner surface of heart; the connection cables that transmit collected signals to the computer system; the hybrid surface equipment with magnetic and electropotential sensors which receives the coordinate information of magnetic sensors on the hybrid catheter and transmits it to the mapping system; the analyzer that includes software that operates the algorithms for identifying the frequency (wavelength), amplitude, location and phase (stimulation sequence) of the magnetic field waves on the specialized conductive tissue and muscle tissue and the methods for separating of these signals from each other and also use the signal collecting and data storage algorithms to create the 3D map of the conduction system and; the computer where the 3D map will be created and monitor that reflects the generated 3D map and the hardware required for the system in which al I equi pment works together.
  • the hybrid catheter can simultaneously collect the heart's biological magnetic field signals and electropotential data from inside the heart (Fig. 1).
  • the catheter sends these signals to the system along with the location information of the sensor.
  • the apparatus (1) located at proximal of the hybrid catheter, allows the electrophysiologist to move the distal tip of the catheter, which reaches into the heart through the vessel from outside the patient (rotation, flexion and change of the diameter of the distal ring, catheter back and forth movement).
  • the hybrid catheter trunk (shaft) length (2) is enough to be extended it into the heart from the inguinal region (femoral vein and artery) of patient.
  • the catheter has data cables (6) to provide connectivity to the mapping system, and contains a special layer (8) that supports the catheter shaft and isolates the internal environment from external signals. In the catheter, there are mechanical wires to reduce the diameter of the distal ring of the catheter (5) and to provide the bending movement (7).
  • the distal portion of the hybrid catheter (3) is in ring configuration during mapping.
  • the catheter contains three chip size (mm size) atomic magnetometers (M1 -3) that receive biological magnetic field signals. These sensors are designed to detect ultra-low, direct current magnetic fields and they are capable of operating in both room and body heat. They provide high resolution magnetic field imaging. These sensors are positioned on the hybrid catheter at x, y, and z coordinates, on perpendicular angles to each other in the 3D environment. On the outer surface of this catheter there are 20 electrodes (pole) (H1-20) with equal spacing to receive electropotential signals (conventional electrodes).
  • a signal transmitter in hybrid catheter that generates ultra- low magnetic field signal with a specific frequency (a special signal band is used other than the biological magnetic signal frequency), which dynamically provides the 3D coordinates of the catheter and magnetometers to the external mapping system.
  • These artificial signals are continuously detected with external magnetic surface sensors.
  • the magnetic field sensitivity of the sensor for the detection of biological magnetic field signals is compatible with magnetic fields between the pico-Tesla and micro-Tesla.
  • the detected signal frequency is at the kHz level.
  • the hybrid catheter simultaneously transmits electropotential and magnetic field signals to the mapping system.
  • the map of the magnetic field based conduction system network is simultaneously created together with conventional electropotential 3D map.
  • reference electroanatomic and magnetic field points (RP 1-6) are marked by hybrid; and activation time intervals (A I 1-12) in heart cycle are determined according to these references.
  • the system performs forward and backward signal analysis at intervals of heart cycle to determine the source of collected signals (Fig. 2). In this way, the device identifies entire magnetic field signals from the conduction system. These identifications can be reconfirmed at each cardiac cycle, as defined in algorithms with electropotential and magnetic field waves that are provided simultaneously by hybrid catheter.
  • the electrophysiologist scans multiple heart cycles for signal collection from different points with hybrid catheter before mapping; and ensures that matchings of the magnetic field signal with their electropotentials are more reliable. After describing biological magnetic field signal frequencies and their location information to the new mapping device, 3D mapping of conduction system is initiated.
  • heart rate and cycle length in ms are determined by the device. Then heart cycle is divided into equal timeslots thousandths of the cardiac cycle; for example, heart cycle in a person with a heart rate of 60 beats per minute takes 1000 ms, and in this way, every equal time interval includes 1 ms in a heart cycle of 1000 ms). Even if heart cycle length and signal formation time change with heart rate, the defined timeslot of signals will be approximately same or equal to the previous beat. During data storage by this method, previous cardiac cycle data matches the next one correctly.
  • Activation intervals (A 1 1-12) that are defined according to the reference points (RP 1- 6) shown in Fig. 2, are scanned by the device for magnetic field signals. Then, before mapping, system matches all signals in a cardiac cycle to the source, using defined reference points (magnetic field signal associated with electrical direct current that occurs during depolarization). For these matchings, analyzes of FSA 1-6 and BSA 1-6 are used. Mapped signals are always recorded in the same timeslot of cardiac cycles. Mapped data is compared with the data in same timeslot in the previous cycle, and the arithmetic average is stored in that timeslot.
  • hybrid catheter is in the H RA region.
  • System scans A 1-1. In this time interval, there is stable basal activity of heart. Signals detected here are defined as basal activity and they are used for filtering frequency band of activation. Then AI-2 is scanned. Magnetic fields in this interval are verified by performing a 2-direction signal scan. Activation wave signals and their locations, originating from the SA node are defined. By A 1-3 and 4 scan, atrial specialized conductive tissue (ACS) is separated from atrial muscle signals (A).
  • ACS atrial specialized conductive tissue
  • the electrical conduction slows down further at the AV node.
  • the transmission of this region is approximately 0.02-0.05 mm/ms.
  • the hybrid catheter is on HIS region. System performs signal scans of AI-5, AI-6 and AI-7 time intervals in turn. With these scans, AV node, HIS bundle and junctional region are scanned and analyzed for biological magnetic signals.
  • Hybrid catheter is moved through the right ventricle (RV) and finally placed in the right ventricular apex. Meanwhile, 5 activation time interval scans from AI-8 to AI-12 are completed. With these scans, infra-HIS region, right and left bundle branch and Purkinje system are mapped. Because these scans are performed from right heart chambers, Purkinje fibers from right ventricle and right bundle branch will be mapped better than that of the left ventricular side. If a better map of conduction system on left heart chambers is desired, those chambers can also be entered separately; and signals can be perceived more closely.
  • Mapping of the specialized connective tissue is carried out by following the signal of activation wave, which is flowing on it (Identification of frequencies for the conduction system are determined by specific signal frequency band that occurs during depolarization). For this reason, the system determines activation intervals of the heart cycle according to reference points and follows only the specific activation wave frequency for conductive tissue at these time intervals. The system searches, collects, and localizes the magnetic field signals of the instantaneous depolarization wave on conduction system. Repolarization and resting phases of heart are not used for the cardiac specialized conductive tissue mapping. These time intervals can be used if desired for substrate mapping of muscle tissue (tissue viability).
  • the system scans the heart cycle for electropotential and magnetic field waves according to the algorithm in Fig. 2, when sinus rhythm is present.
  • the identification process of signal differences is performed to be used during tachycardia by the system.
  • basal artifact signals (BA)
  • muscle and other tissue signals aside from specialized conductive tissue are determined; and they are used to filter during the tachycardia mapping.
  • Signals originating from muscle tissue are not used for the activation map of conductive tissue.
  • t signals especially when the conduction system is active, PR interval for atrium (PRI, PR interval, the system maps the conduction system from the atrium to the Purkinje system), and pre-systolic interval (20 ms before the Q wave on surface E CG, and before V wave on intracardiac measurements) for ventricles, are recorded while hybrid catheter is moved through the mapped heart chamber.
  • PRI PR interval
  • pre-systolic interval 20 ms before the Q wave on surface E CG, and before V wave on intracardiac measurements
  • the conduction system map can be generated even for each heart cycle.
  • the conduction system map will be clearer, especially by signal coordinate combining process, which coordinates obtained for each heartbeat are averaged with the previous one. Coordinates of traditional 3D electroanatomical map are equalized to the actual CS anatomy by overlapping of the CS catheter; and the magnetic field map by the HIS electroanatomical reference point.
  • the system uses specific frequency of magnetic field sources as a marker/indicator for these structures (SA, AV, HIS, conduction pathways, Purkinje tissue).
  • SA atrial structures and AV conduction
  • the signal scanning is performed at time intervals from AI-2 to A 1-8, and for ventricular assessment at A 1-9 and 10.
  • Other AIs are used to filter the magnetic fields originating from outside the conduction system during the map, and their analysis is not required in every cardiac cycle.
  • the hybrid catheter is firstly moved through the right atrium and then in the right ventricle and, if necessary, in the left ventricle. Left atrium can be mapped from inside the right atrium.
  • the system reconstructs the conduction system 3D map in each new heartbeat and in each different position of Hybrid catheter; and so that, the signal location information is compared with that of same timeslots in previous cycles. As a result of these comparisons, the precise course of conduction system pathways in 3D environment is formed.
  • the conduction system shape is plotted with graph of the activation wave signal coordinate, against the timeslot of heart cycle in 3D environment.
  • tachycardia is induced to be initiated by traditional methods. Since the stimulation sequence of the heart will change during tachycardia, the signal scanning cannot be performed in AIs defined according to RPs. The device no longer accepts as new cardiac cycle within the time between RR waves; and scans all signals, in new defined timeslots (thousandths of RR) without time interval for tachycardia mapping. Previously, location information, depolarization wave frequency and amplitude values that were defined as signals for the conductive tissue, are searched between new scanned signals during tachycardia (these signals are determined by the magnetic field signal frequency generated during phase 0 of the cardiac action potential).
  • Signals of the conductive tissue are selected and others are eliminated.
  • the new course of the depolarization wave transmitted on the atrium and ventricular specialized conduction pathways is mapped in 3D, during tachycardia. If there is a signal that cannot be recognized by the system during tachycardia, the electrophysiologist can manually assign this signal to the system by comparing it with the electropotential sequence.
  • the new system can only scan the frequency of conductive tissue and can only extract the 3D map of the conduction system propagation pattern. This mapping style may provide information of the conduction system has an active role in the development of tachycardia or not. If the conduction system is actively involved in tachycardia, it provides information about critical point will be effective in the ablation treatment or not.
  • SA sinoatrial node
  • AV node AV node
  • HIS right-left bundle branches
  • the map resolution reduces at the distal end points (Purkinje fibers), where the conduction system is tapered and distributed into the ventricles. If the pathology is detected in these distal areas, the hybrid mapping catheter is brought closer to the relevant area and the pathologic focus is better localized.
  • the device determines where the activation wave is instantly on the conduction system in each timeslot along the cardiac cycle.
  • the activation wave is recorded when it is on muscle tissue, the activation line can be mapped as a region rather than as a point of the line. The reason is that electrical transmission spreads over wide regions on muscle tissue, while it spreads on a line over the conduction system.
  • the mapping catheter is contacted with muscle tissue in the mapped heart chamber. This means that the resolution of the map will increase in a manner directly proportional to the number of contacts. With the new method, direct contact is not necessary as magnetic field signals are mapped.
  • the entire conductive tissue map can be extracted without catheter contact from a single position, but in order to elaborate the map of the intended region, it will be necessary to collect data from points closer to that area. However, it is unlikely to reveal completely the conductive tissue pathways on the basis of traditional 3D electropotential measurement.
  • the signal location information is collected and stored at appropriate timeslots, according to changing dynamic positions of sensor and biological magnetic field sources (Fig. 3).
  • the activation wave spreads from SA node to AV node and then to HIS-Purkinje system via the specialized conductive tissue pathways (F3- A).
  • the device records by focusing on the specific frequency of activation wave in defined timeslots of heart cycle.
  • Hybrid catheter is at a fixed point, signals are recorded separately for each timeslot.
  • the activation wave acts at a rate of about 1-4 mm/ms, with different properties on atrial and ventricular segments of the conduction system.
  • the location of magnetic field source with specific frequency of conductive tissue in each timeslot is calculated for the 3 magnetosensors on the hybrid catheter, with reverse problem solving technique.
  • the device collects signal location information for the same timeslot at different positions of hybrid catheter; and compares this information with data obtained from sensors that are simultaneously present at different positions.
  • the instantaneous signal location data defined for a given timeslot in each heart cycle is verified (F3-B).
  • the signals that are received for 140th ms are recalculated in each new heart cycle, while the sensor is located at different distances to the signal source.
  • the activation wave can be localized more precisely where it is on the conduction system for a moment.
  • the activation wave (depolarization) location information on the conductive tissue will be on a specific point or transmission line (pathway) rather than a broad area, unlike the activation wave of the muscle tissue. While the activation wave on the conductive tissue moves to a certain direction and on the pathway; it spreads over an area on muscle tissue. For this reason, instead of activation map with sharply defined distinct lines, the areas of muscle tissue presenting with broad activation sites on the current 3D mapping can be visualized. By the new mapping method presented here, this deficiency is also eliminated.
  • the system firstly measures between two R -waves (V-wave on the intracardiac records, the R-wave of the QRS on the surface E CG) in ms and determines the cardiac cycle. This time is divided by 1000 (0.1 % of cycle).
  • the cardiac cycle in a person with a heart rate of 60 beats per minute takes 1000 ms; and every equal timeslot includes 1 ms in a heart cycle of 1000 ms.
  • the system begins the signal scanning at the RP-1 point of heart cycle and ends it at the same point of the next cycle.
  • the electrophysiologist marks some critical reference points (magnetic signals and electropotentials) on this raw hybrid data scan for the system (P, A wave, PA interval, A H and HV interval, QRS and V waves, and T wave, RPs).
  • Fig. 2 shows which regions of the heart are electrically activated; and which regions are at rest in these time intervals (A I 1-12). E lectropotential and magnetic field data are recorded simultaneously.
  • the system analyzes the time intervals on the algorithm (Fig. 2) and the magnetic fields of each active structure are identified separately.
  • depolarized, repolarized and deactivated intervals are determined. After this scan, the specific frequency of activation (depolarization) wave for the conduction system is determined. The frequencies of other tissues are also defined for the filtering process. Magnetic field frequencies, activation amplitudes and anatomical location information of SA node, intra/interatrial conduction system (ACS), AV node, HIS-Purkinje system are saved by the system. This pre-mapping information is then used in the real scanning and mapping.
  • the new system By using a mathematical model template defined for conduction system pathways, the new system generates high resolution 3D map of the conduction system during both sinus rhythm and tachycardia, by processing of position data of the Hybrid mapping catheter and signals obtained from the conduction system in defined timeslots of heart cycle.
  • the difference in two maps created during sinus rhythm and tachycardia is not the actual anatomical structure of conduction system, it is the information about the beginning point of activation wave spreads to other points on this network.
  • the new generated 3D map is positioned on the electroanatomical map that is obtained by the conventional 3D method; and it is determined if the conduction system is the main arrhythmia source or it has a critical anatomical point for arrhythmia. In this way, only one- point ablation for arrhythmia treatment may be sufficient rather than an area.
  • points where the conduction system is active are placed on the 3D coordinate system for all timeslot of cardiac cycle.
  • the system uses reverse problem solving technique to detect the source of biological magnetic field.
  • the system simultaneously records all of magnetic field signals incoming from 3 magnetosensors located on the coordinates of Hybrid catheter. Magnetosensors " 3D positions are continuously monitored by the mapping system. All selected signals are analyzed by computer with reverse problem solving method and they are localized to one or more 3D points.
  • Separation of conductive tissue magnetic field signals from muscle tissue signals can be provided with difference in time domain, strength of magnetic field and frequency domain of them. Using these differences, the system places signals on the 3D model, calculating the source-sensor distance.
  • the activation wave of conduction system is transmitted on specialized conductive tissue pathways, from the SA node until Purkinje fibers.
  • the signal source travels sometimes on one line at a single point, and sometimes simultaneously on more than one anatomical point on the network of conductive structures.
  • the new mapping system re-analyzes the data received from multiple sensors at the same timeslot with varying sensor distances and multiple source information.
  • the mapping system evaluates the magnetic field signal detected by the sensor, it selects the specific frequency band of conduction system, defined prior to the tachycardia mapping (in pre- mapping evaluation). Then the system compares data collected for each timeslot of heart cycle.
  • location of signal source obtained with reverse problem solving is compared with the location data that is calculated while the hybrid catheter is at different positions in the same chamber. If there is a deviation in the calculated signal source location information, with more than acceptable error, new mapping system determines that detected signals by different sensors in the same frequency band and the same timeslot are originated from locations more than one point on the conduction system. The system recalculates source distances by changing the number and location of the source variables in the reverse problem solving technique. The number of active magnetic field signal source and location information that can be verified for all sensor locations are marked on the 3D map as signal source points where the conduction system is active at 140th ms (3D location graph against time). The hybrid catheter is moved to different locations at each heartbeat and calculated coordinates for the map are clarified.
  • Tachycardia is induced after anatomical mapping of the conduction system is completed. During tachycardia, all signals are re- scanned by Hybrid catheter during a heart cycle. The activation pattern of the conduction system is reconstructed during tachycardia. This pattern is placed on the conventional 3D electroanatomic map. Critical points/pathways of the conduction system that involve the tachycardia are shown on this map. If a point on the conduction system is an active part of the tachycardia main pathway or the initiator of the tachycardia, the determined point is ablated.
  • the specialized conductive tissue pathways unlike the muscles in the heart, are located on a narrow line. For this reason, the actual anatomical patterns of conduction system pathways in all of cardiac chambers and the possible changes of distance must be determined. Because, reverse problem solving method basically uses this anatomical modeling in the detection of magnetic field sources. Using this model, the system places the signals detected at different points on the conduction system on the 3D map with high accuracy. In this model, the coordinates at which all possible signals can be located for each position of the magnetometers inside the heart are predetermined. If the conductive tissue map reveals a new path other than the predicted conduction system pathways, it is referred to as "the accessory path".
  • the new mapping method can simultaneously detect magnetic field signals beyond the heart chamber in which the mapping catheter is located.
  • the catheter can detect the signals at good quality from other heart chambers where magnetic field signals can reach the sensor simultaneously.
  • the map of the heart chamber in which the sensor is located will have a higher resolution than other chambers, but this additional feature will guide the electrophysiology to direct the source of the arrhythmia.
  • the computer software includes the methods to operate the algorithms that are necessary to distinguish the magnetic field signals from each other and from other signals inside and outside of the heart. It also contains the order in which the data will be identified and the interpretation will be performed.
  • the mapping system uses the data obtained by taking a record for each timeslot during the mapping (by millisecond-level recording rate). In pre-mapping evaluation before tachycardia mapping by the new mapping system, the electropotentials of the heart's conductive tissues (SA, HIS) are matched to their magnetic field signals. The device then completes the missing fields of the conduction system in each new heartbeat, in accordance with the algorithms defined for it (AV node, intraatrial conductive tissues, right and left bundle branches and Purkinje system).
  • the software uses a partial artificial intelligence algorithm for comparison of the data and establishment of locations, and to el i mi nate the i mpossi bl e I ocati on opti ons.
  • a special Hybrid signal collection catheter is used instead of the mapping catheter used in the conventional 3D mapping method for signal acquisition.
  • Ablation treatment can be achieved with conventional ablation catheters that can be identified in the new system.
  • the device that has the capability of a hybrid working with state-of-the-art electroanatomical mapping systems includes a special hybrid catheter that simultaneously collect the electropotentials and endocardial biological magnetic field signals from the inner surface of the heart; the connection cables that transmit the collected signals to the computer system; the hybrid surface equipment with magnetic and electropotential sensors which receives the coordinate information of magnetic sensors on Hybrid catheter from outside of the patient and transmits it to the mapping system; the analyzer that includes software that operates the algorithms for identifying the frequency (wavelength), amplitude, location and phase (stimulation sequence) of the magnetic field waves on the specialized conductive tissue and muscle tissue and the methods for separating of these signals from each other and also use the signal collecting and data storage algorithms to create the 3D map of the conduction system and; the computer where the 3D map will be created and monitor that reflects the generated 3D map and the hardware required for the system in which all equipment works together.
  • the analyzer on which the data is processed and analyzed, and the computer on which the 3D map is created are the main elements of the device.
  • a more memory space and faster processor support in computer is required for the analysis of the acquired data, since a faster and more frequent scan is performed in mapping the conduction system according to the conventional 3D method.
  • a new device will be developed to increase the success rates of diagnosis and treatment of cardiac rhythm disorders.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Psychiatry (AREA)
  • Signal Processing (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)

Abstract

L'invention concerne un dispositif qui comprend un cathéter hybride spécial qui recueille les potentiels électriques et les signaux de champ magnétique biologiques endocardiques provenant de la surface interne du coeur. De plus, des câbles de connexion qui transmettent ces signaux au système informatique et à un équipement de surface hybride par des capteurs magnétiques et de potentiels électriques, qui reçoivent les informations de coordonnées de capteurs magnétiques sur un cathéter hybride et les transmettent au système de cartographie, sont également requis. L'invention concerne également un analyseur qui comprend un logiciel qui utilise des algorithmes pour identifier la fréquence, l'amplitude, l'emplacement et la phase (séquence de stimulation) d'ondes de champ magnétique sur des tissus conducteurs et des tissus musculaires spécialisés et exécute des procédés de séparation de ces signaux les uns des autres, et utilise également les algorithmes de collecte de signaux et de stockage de données pour créer la carte 3D du système de conduction. L'invention concerne en outre un ordinateur au moyen duquel la carte sera créée; un moniteur qui fait apparaître la carte générée; et un matériel requis pour le système.
PCT/TR2017/050230 2017-04-10 2017-05-31 Amélioration de systèmes de cartographie électro-anatomique tridimensionnelle traditionnelle sur la base de mesure de potentiel électrique par cartographie de signal de champ magnétique biologique endocardique : cartographie de tissu conducteur cardiaque WO2018190781A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/05242 2017-04-10
TR2017/05242A TR201705242A2 (tr) 2017-04-10 2017-04-10 Geleneksel elektropotansiyel ölçüm temelli 3 boyutlu elektroanatomik haritalama yöntemlerinin endokardiyal biyolojik manyetik alan sinyalleri ile geliştirilmesi: İleti dokusu haritalama

Publications (1)

Publication Number Publication Date
WO2018190781A1 true WO2018190781A1 (fr) 2018-10-18

Family

ID=60001989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2017/050230 WO2018190781A1 (fr) 2017-04-10 2017-05-31 Amélioration de systèmes de cartographie électro-anatomique tridimensionnelle traditionnelle sur la base de mesure de potentiel électrique par cartographie de signal de champ magnétique biologique endocardique : cartographie de tissu conducteur cardiaque

Country Status (2)

Country Link
TR (1) TR201705242A2 (fr)
WO (1) WO2018190781A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111214287A (zh) * 2018-11-26 2020-06-02 韦伯斯特生物官能(以色列)有限公司 查找心律失常的源点
CN114269272A (zh) * 2019-04-18 2022-04-01 阿库图斯医疗有限公司 创建复合标测图的系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5782824A (en) * 1993-09-20 1998-07-21 Abela Laser Systems, Inc. Cardiac catheter anchoring
US20040152974A1 (en) * 2001-04-06 2004-08-05 Stephen Solomon Cardiology mapping and navigation system
WO2007134190A2 (fr) * 2006-05-10 2007-11-22 Regents Of The University Of Minnesota Procédé et appareil d'imagerie électrophysiologique cardiaque en trois dimensions
WO2015085011A1 (fr) * 2013-12-04 2015-06-11 Obalon Therapeutics , Inc. Systèmes et procédés de localisation et/ou de caractérisation de dispositifs intragastriques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5782824A (en) * 1993-09-20 1998-07-21 Abela Laser Systems, Inc. Cardiac catheter anchoring
US20040152974A1 (en) * 2001-04-06 2004-08-05 Stephen Solomon Cardiology mapping and navigation system
WO2007134190A2 (fr) * 2006-05-10 2007-11-22 Regents Of The University Of Minnesota Procédé et appareil d'imagerie électrophysiologique cardiaque en trois dimensions
WO2015085011A1 (fr) * 2013-12-04 2015-06-11 Obalon Therapeutics , Inc. Systèmes et procédés de localisation et/ou de caractérisation de dispositifs intragastriques

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BISON G ET AL: "A room temperature 19-channel magnetic field mapping device for cardiac signals", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 26 June 2009 (2009-06-26), XP080331308, DOI: 10.1063/1.3255041 *
JOHN KITCHING ET AL: "Microfabricated atomic magnetometers and applications", FREQUENCY CONTROL SYMPOSIUM, 2008 IEEE INTERNATIONAL, IEEE, PISCATAWAY, NJ, USA, 19 May 2008 (2008-05-19), pages 789 - 794, XP031319976, ISBN: 978-1-4244-1794-0 *
KNAPPE S ET AL: "Microfabricated atomic clocks and magnetometers", JOURNAL OF OPTICS. A, PURE AND APPLIED OPTICS, INSTITUTE OF PHYSICS PUBLISHING, BRISTOL, GB, vol. 8, no. 7, 1 July 2006 (2006-07-01), pages S318 - S322, XP020108490, ISSN: 1464-4258, DOI: 10.1088/1464-4258/8/7/S04 *
MINA ATTIN: "Electrophysiology Study: A Comprehensive Review", AMERICAN JOURNAL OF CRITICAL CARE, vol. 10, no. 4, 1 July 2001 (2001-07-01), pages 260 - 273, XP055430655 *
ROBBES D ET AL: "Feasibility of an intra-cardiac magnetic probe", PHYSIC, NORTH-HOLLAND PUBLISHING, AMSTERDAM, NL, vol. 372-376, 1 August 2002 (2002-08-01), pages 249 - 253, XP004375404, ISSN: 0921-4534, DOI: 10.1016/S0921-4534(02)00682-2 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111214287A (zh) * 2018-11-26 2020-06-02 韦伯斯特生物官能(以色列)有限公司 查找心律失常的源点
CN111214287B (zh) * 2018-11-26 2023-07-04 韦伯斯特生物官能(以色列)有限公司 查找心律失常的源点
US11857307B2 (en) 2018-11-26 2024-01-02 Biosense Webster (Israel) Ltd. Finding the origin of an arrythmia
CN114269272A (zh) * 2019-04-18 2022-04-01 阿库图斯医疗有限公司 创建复合标测图的系统

Also Published As

Publication number Publication date
TR201705242A2 (tr) 2018-10-22

Similar Documents

Publication Publication Date Title
US7123954B2 (en) Method for classifying and localizing heart arrhythmias
US6308093B1 (en) Method and apparatus for guiding ablative therapy of abnormal biological electrical excitation
EP2335571B1 (fr) Cartographie stimulée automatique pour l'identification des voies conductrices et foyers arythmiques cardiaques
US6760620B2 (en) Non-invasive localization and treatment of focal atrial fibrillation
EP2723230B1 (fr) Localisation assistée par ordinateur d'un site d'origine d'activation cardiaque
EP2948053B1 (fr) Localisation assistée par ordinateur de site d'origine d'activation cardiaque à l'aide des sondes de discrimination
WO2001025822A1 (fr) Procede et appareil de guidage destines a la therapie d'ablation d'une excitation bioelectrique anormale
EP3270776A1 (fr) Systèmes et procédés pour une détection indépendante d'une orientation
WO1997017893A9 (fr) Systeme et methode d'analyse des ondes electrographiques
JPH11511666A (ja) 生物学的事象の時系列計測を行うためのシステム及び方法
US20230181087A1 (en) Intracardiac unipolar far field cancelation using multiple electrode cathethers
Kemmelings et al. Automatic QRS onset and offset detection for body surface QRS integral mapping of ventricular tachycardia
WO2018190781A1 (fr) Amélioration de systèmes de cartographie électro-anatomique tridimensionnelle traditionnelle sur la base de mesure de potentiel électrique par cartographie de signal de champ magnétique biologique endocardique : cartographie de tissu conducteur cardiaque
US11464437B2 (en) Mid-field signal extraction
JP2021079099A (ja) 心内心電図における異常な興奮を見つけるための方法
US20230181246A1 (en) Cardiac vein ablation visualization system and catheter
US20220192576A1 (en) Cardiac mapping via near-field identification from physiological signals
JP7726468B2 (ja) 二重電位問題の解決
EP4447805A1 (fr) Annulation de champ lointain unipolaire intracardiaque à l'aide de cathéters à électrodes multiples
He et al. An interactive graphical system for automated mapping and display of cardiac rhythms
WO2023105493A1 (fr) Système et cathéter de visualisation d'ablation de veine cardiaque
Ueda et al. Dimensional Mapping Systems
JP2025010065A (ja) 多電極カテーテルを使用した心内単極遠方場の相殺、並びにｅｃｇ深さ及び径方向レンズを作成する方法
ABNORMAL I 11111 111111ll Ill11 Ill11 us00030~ 003 IIIII 111l Il11 IIIII I< Ill11 IIIII 111ll1111111ll1111
Vahlhaus et al. Role of Body Surface Mapping

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17777998

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17777998

Country of ref document: EP

Kind code of ref document: A1